Martha Geoffrey 4
4 · Medtronic plc · Filed Aug 4, 2025
Insider Transaction Report
Form 4
Martha Geoffrey
DirectorChairman and CEO
Transactions
- Exercise/Conversion
Ordinary Shares
2025-08-01+57,724→ 283,700 total - Tax Payment
Ordinary Shares
2025-08-01$89.34/sh−13,054$1,166,244→ 244,323 total - Tax Payment
Ordinary Shares
2025-08-01$89.34/sh−37,798$3,376,873→ 247,125 total - Exercise/Conversion
Performance Share Units
2025-08-01−57,724→ 0 total→ Performance Share Unit (57,724 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-08-01−40,600→ 0 totalExercise: $78.00Exp: 2025-08-03→ Ordinary Shares (40,600 underlying) - Tax Payment
Ordinary Shares
2025-08-01$89.34/sh−26,323$2,351,697→ 257,377 total - Exercise/Conversion
Ordinary Shares
2025-08-01$78.00/sh+40,600$3,166,800→ 284,923 total
Footnotes (6)
- [F1]Represents shares issued upon the settlement of performance-vesting restricted stock units granted on August 1, 2022 and earned dividend equivalents.
- [F2]Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on August 1, 2025.
- [F3]Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I.
- [F4]Each performance share unit represents a contingent right to receive one share of Medtronic common stock.
- [F5]The performance share units vested on August 1, 2025.
- [F6]These options became exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.